BNIP3 as a potential biomarker for the identification of prognosis and diagnosis in solid tumours
© 2023. BioMed Central Ltd., part of Springer Nature..
BACKGROUND: Traditional radiotherapy and chemotherapy have been intensively studied for their role in the treatment of tumours. However, these therapies often cause side effects for patients, which calls for the development of novel treatment options for tumours. B-cell lymphoma-2 (Bcl-2)/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) reportedly apoptosis-inducing effects in tumour cells and is associated with the progression and treatment of multiple tumours. Nevertheless, little is known about its potential role in tumour diagnosis and targeted therapy.
FINDINGS: The results of the study demonstrated that the interaction of BNIP3 with HDAC1 may affect the progression of breast invasive cancer (BRCA), sarcoma (SARC), kidney renal clear cell carcinoma (KIRC), and low-grade glioma (LGG). BNIP3 seemed to exert its effects in BRCA and SARC primarily through gene silencing and integrator complex, and in KIRC and LGG, mainly by affecting olfactory function, suggesting that targeted therapy can be developed based on the above signalling pathway and downstream molecules.
INTERPRETATION: BNIP3 has emerged as a promising therapeutic and diagnostic target for BRCA, SARC, KIRC, and LGG, providing new insights into tumour molecular therapies in the clinic.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Molecular cancer - 22(2023), 1 vom: 30. Aug., Seite 143 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yu, Qin [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
BNIP3 |
|---|
| Anmerkungen: |
Date Completed 01.09.2023 Date Revised 21.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12943-023-01808-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM361469101 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM361469101 | ||
| 003 | DE-627 | ||
| 005 | 20231226085213.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12943-023-01808-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1204.xml |
| 035 | |a (DE-627)NLM361469101 | ||
| 035 | |a (NLM)37649051 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yu, Qin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a BNIP3 as a potential biomarker for the identification of prognosis and diagnosis in solid tumours |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.09.2023 | ||
| 500 | |a Date Revised 21.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. BioMed Central Ltd., part of Springer Nature. | ||
| 520 | |a BACKGROUND: Traditional radiotherapy and chemotherapy have been intensively studied for their role in the treatment of tumours. However, these therapies often cause side effects for patients, which calls for the development of novel treatment options for tumours. B-cell lymphoma-2 (Bcl-2)/adenovirus E1B 19 kDa-interacting protein 3 (BNIP3) reportedly apoptosis-inducing effects in tumour cells and is associated with the progression and treatment of multiple tumours. Nevertheless, little is known about its potential role in tumour diagnosis and targeted therapy | ||
| 520 | |a FINDINGS: The results of the study demonstrated that the interaction of BNIP3 with HDAC1 may affect the progression of breast invasive cancer (BRCA), sarcoma (SARC), kidney renal clear cell carcinoma (KIRC), and low-grade glioma (LGG). BNIP3 seemed to exert its effects in BRCA and SARC primarily through gene silencing and integrator complex, and in KIRC and LGG, mainly by affecting olfactory function, suggesting that targeted therapy can be developed based on the above signalling pathway and downstream molecules | ||
| 520 | |a INTERPRETATION: BNIP3 has emerged as a promising therapeutic and diagnostic target for BRCA, SARC, KIRC, and LGG, providing new insights into tumour molecular therapies in the clinic | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a BNIP3 | |
| 650 | 4 | |a Diagnosis | |
| 650 | 4 | |a Immune infiltration | |
| 650 | 4 | |a Pan-cancer analysis | |
| 650 | 4 | |a Prognostic biomarker | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a BNIP3 protein, human |2 NLM | |
| 650 | 7 | |a Membrane Proteins |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins |2 NLM | |
| 700 | 1 | |a Fu, Wenhao |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Yutang |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Wenjing |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Huiqiong |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Zecheng |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ruirui |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Yili |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yuxin |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Lingyun |e verfasserin |4 aut | |
| 700 | 1 | |a Wei, Xianqiao |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yangkun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yuheng |e verfasserin |4 aut | |
| 700 | 1 | |a Ying, Huazhong |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Furong |e verfasserin |4 aut | |
| 700 | 1 | |a Dai, Fangwei |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Wei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular cancer |d 2002 |g 22(2023), 1 vom: 30. Aug., Seite 143 |w (DE-627)NLM120915979 |x 1476-4598 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:1 |g day:30 |g month:08 |g pages:143 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12943-023-01808-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 1 |b 30 |c 08 |h 143 | ||